LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling

While the antiandrogen enzalutamide (Enz) extends the castration resistant prostate cancer (CRPC) patients’ survival an extra 4.8 months, it might also result in some adverse effects via inducing the neuroendocrine differentiation (NED). Here we found that lncRNA-p21 is highly expressed in the NEPC...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nat Commun
Autors principals: Luo, Jie, Wang, Keliang, Yeh, Shuyuan, Sun, Yin, Liang, Liang, Xiao, Yao, Xu, Wanhai, Niu, Yuanjie, Cheng, Liang, Maity, Sankar N., Jiang, Runze, Chang, Chawnshang
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6561926/
https://ncbi.nlm.nih.gov/pubmed/31189930
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-019-09784-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars